Clinical trial
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression…
NCT00158860 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00158860 |
|---|---|
| Title | A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies. |
| Official title | An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Herpes Genitalis |
| Intervention type | Drug |
| Interventions | Valaciclovir, Placebo |
| Enrollment | 384 |
| Start date | Jun 21, 2004 |
| Primary completion | Jul 26, 2006 |
| Completion | Jul 26, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Feb 15, 2019 |
| Countries | Argentina, Brazil, Canada, Chile, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: